SecBot SecBot
PTAB-TRIAL ·Filed Nov 9, 2026

MRK

Merck & Co., Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed7d 4h ago PTABPTAB Decision · ptacts.uspto.gov
PTAB final written decision
Actionable Insight • Neutral

The invalidation removes one patent from the ongoing Halozyme-Merck litigation, but many related patents remain in dispute. Monitor the remaining PGRs and the district court case for further developments.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$148.05
T+0 close · Nov 9, 2026 · via day close
Latest settled
−0.59%
T+1 · $147.18
Vs SPY
−1.91%
α at T+1
Next horizon
T+5
in 7h
  1. T+0 · Nov 10 $148.05entry
  2. T+1 · 6d ago −0.59%α −1.91% · $147.18
  3. T+4 · todayOpen
  4. T+5 · in 7h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

Executive Summary

In a final written decision, the PTAB held all challenged claims (1, 2, 5, and 7–33) of Halozyme's PH20 hyaluronidase patent unpatentable on written description, enablement, and obviousness grounds. Merck Sharp & Dohme LLC, the petitioner, succeeded in invalidating the patent, which is part of a broader patent dispute between Halozyme and Merck.

PTAB Trial Details

Proceeding
PGR2025-00042
Proceeding Type
PGR (post-grant review)
Decision
Final written decision
Company Role
Petitioner
Outcome for Patent Owner
Loss
Patent
U.S. 12,037,618
Patent Covers
Modified PH20 hyaluronidase polypeptides with increased stability and/or activity
Challenged Claims
1, 2, 5, 7–33
Claims Cancelled
1, 2, 5, 7–33
Related Litigation
Halozyme, Inc. v. Merck Sharp & Dohme LLC f/k/a/ Merck Sharp & Dohme Corp., 2:25-cv-03179 (D.N.J.)
Next Step
Parties seeking judicial review must comply with 37 C.F.R. § 90.2 (appeal to Federal Circuit).

Key Facts

  • PTAB issued a final written decision in PGR2025-00042, finding claims 1, 2, 5, and 7–33 of U.S. Patent 12,037,618 unpatentable.
  • The patent covers modified PH20 hyaluronidase polypeptides with increased stability and/or activity.
  • Merck Sharp & Dohme LLC (a subsidiary of Merck & Co.) was the petitioner; Halozyme, Inc. was the patent owner.
  • The decision is based on lack of written description, lack of enablement, and obviousness over the '429 patent and Chao prior art.
  • The '618 patent is one of many patents in a related district court action (Halozyme v. Merck, 2:25-cv-03179 D.N.J.) and multiple other PGRs and IPRs.

Financial Impact

Not stated in the decision; no financial figures provided.

Risk Factors

  • The decision may be appealed to the Federal Circuit; the patent could be reinstated.
  • Other related patents in the same family are still being challenged in separate PTAB proceedings and the district court.

Market Snapshot

Price
$148.73
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 PTAB decision.

DocumentAccession Number
PTAB-TRIAL Data (Synthetic)ptab-PGR2025-00042-fwd-MRK

Track record

34 reports on MRK

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 Now $144.46 −2.23% settles Feb 11
  2. Nov 9, 20268d ago PTAB Trial Neutral 2/10 Viewing Entry $148.05 Now $144.46 −2.42% settles Feb 8
  3. Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
  4. Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $144.46 +0.15% settles Feb 1
  5. Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
  6. Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $144.46 −1.28% settles Jan 27
  7. Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $144.46 −0.56% settles Jan 21
  8. Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $144.46 −1.89% settles Jan 20
  9. Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
  10. Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time PTAB Decision Intelligence

Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ PTAB Decision · ptacts.uspto.gov Report published Nov 9, 2026